Table 1 Baseline demographics characteristics
Characteristics | A1 cohort (n = 11) | A2 cohort (n = 6) | B1 cohort (n = 12) | B2 cohort (n = 121) | All (n = 150) |
|---|---|---|---|---|---|
Age, median (range, y) | 61 (41, 65) | 50 (33, 67) | 59 (26, 71) | 60 (29, 77) | 60 (26, 77) |
Sex, no. (%) | |||||
Female | 9 (81.8) | 2 (33.3) | 10 (83.3) | 61 (50.4) | 82 (54.7) |
Male | 2 (18.2) | 4 (66.7) | 2 (16.7) | 60 (49.6) | 68 (45.3) |
Histologic type, no. (%) | |||||
Adenocarcinoma | 11 (100) | 6 (100) | 12 (100) | 119 (98.3) | 148 (98.7) |
Squamous cell carcinoma | 0 | 0 | 0 | 1 (0.8) | 1 (0.7) |
Adenosquamous | 0 | 0 | 0 | 1 (0.8) | 1 (0.7) |
ECOG performance status, no. (%) | |||||
0 | 4 (36.4) | 2 (33.3) | 2 (16.7) | 15 (12.4) | 23 (15.3) |
1 | 7 (63.6) | 4 (66.7) | 10 (83.3) | 106 (87.6) | 127 (84.7) |
History of smoking, no. (%) | |||||
Never | 9 (81.8) | 4 (66.7) | 11 (91.7) | 78 (64.5) | 102 (68.0) |
Ever | 2 (18.2) | 2 (33.3) | 1 (8.3) | 43 (35.5) | 48 (32.0) |
Disease stage, no. (%) | |||||
IV | 10 (90.9) | 6 (100) | 11 (91.7) | 119 (98.3) | 146 (97.3) |
IIIB | 0 | 0 | 1 (8.3) | 0 | 1 (0.7) |
Prior systemic therapies | |||||
Median (range) | 1 (0, 6) | 1 (1, 3) | 1 (0, 6) | 1 (0, 7) | 1 (0, 7) |
Prior systemic anticancer regimens, no. (%) | |||||
Chemotherapy | 10 (91.9) | 5 (83.3) | 7 (58.3) | 63 (52.1) | 85 (56.7) |
EGFR TKI | 1 (9.1) | 1 (16.7) | 5 (41.7) | 16 (13.2) | 23 (15.3) |
Baseline CNS metastases, no. (%) | |||||
Yes | 4 (36.4) | 3 (50.0) | 6 (50.0) | 62 (51.2) | 75 (50.0) |
No | 7 (63.6) | 3 (50.0) | 6 (50.0) | 59 (48.8) | 75 (50.0) |
